GELSECTAN® and Covert Hepatic Encephalopathy

Learn more about:
Related Clinical Trial
GELSECTAN® and Covert Hepatic Encephalopathy Early Diagnosis and Timely Treatment of Cirrhotic Patients With Minimal Hepatic Encephalopathy (CHESS-NCRCID 2106) Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis A Randomized Open-label Trial of Deprescribing Proton Pump Inhibitors to Reduce the Risk of Hepatic Encephalopathy After Transjugular Intrahepatic Portosystemic Shunt Creation Feasibility of an App-based Nutrition & Exercise Program in Cirrhosis Eye Movement Testing for Diagnosing Encephalopathy in Patients With Liver Disease VE303 for Treatment of Hepatic Encephalopathy (HE) Efficacy and Safety of AXA1665 in Cirrhotic Subjects With Prior Overt Hepatic Encephalopathy The Effect of Induced Hyperammonaemia on Sleep and Melanopsin-mediated Pupillary Light Response in Patients With Liver Cirrhosis Microbial Resistance of Rifaximin in Hepatic Encephalopathy Establishment of the Human Intestinal and Salivary Microbiota Biobank – Gastrointestinal Diseases The BRAINFOOD Trial to Prevent Recurrent Hepatic Encephalopathy. HepQuant to Predict Hepatic Encephalopathy After TIPS Polyethylene Glycol Versus Lactulose on Hepatic Encephalopathy in Patients With Cirrhosis;(PEGHE Trial) Flicker App for Minimal Hepatic Encephalopathy Prognostic Significance of Fatty Liver Disease in Bariatric Patients Timing of Acute Palliative Care Consultation in Critically Ill Patients Effects of Branched-Chain Amino Acids on Muscle Ammonia Metabolism in Patients With Cirrhosis and Healthy Subjects The Effect of Prometheus (R) Liver Support Dialysis on Cerebral Metabolism in Acute Liver Failure Tackling 30-day Readmissions in Patients With Cirrhosis: The SALTYFOOD Trial A Multi-Center Group to Study Acute Liver Failure in Children The Effect of a Large-volume Paracentesis on Fatigue, Sleep, and Quality of Life in Cirrhosis Factors Associated With End Stage Liver Disease Monitoring of Encephalopathy in Cirrhotic Patients Admitted in Intensive Care A Study of MHE in Patients With Liver Diseases Effect of Midodrine and Albumine in the Prevention of Complications in Cirrhotic Patients Awaiting Liver Transplantation Effect of Transjugular Intrahepatic Portosystemic Shunt on Gut Microbiota in Cirrhotic Patients Quantitative Determination of Brain Water Content in Patients During and After Hepatic Encepalopathy Prediction of Mortality in Patients Waiting for Liver Transplantation Through Brain Magnetic Resonance Imaging Oral Fecal Transplant in Cirrhosis Bioelectrical Impedance Vector Analysis in Cirrhotic Patients Therapeutic Efficacy of Oral L-Ornithine-L-Aspartate on Minimal Encephalopathy Trial Comparing Sedation for Endoscopy With Propofol Versus Midazolam in Cirrhotics Manganese in Women With Encephalopathy Brain Energy Metabolism in Patients With Chronic Liver Disease and Impaired Central Nervous System Comparison Between Lactulose and Lactulose-Paraffin in Cirrhotic Patients Effect of Probiotics in Treatment of Minimal Hepatic Encephalopathy (MHE) and Health Related Quality of Life Study of Lactulose in Children With Chronic Liver Disease Reversibility of Minimal Hepatic Encephalopathy Following Liver Transplantation Early Postoperative CRRT After Liver Transplantation in ACLF Patients With Overt HE N-acetylcysteine in Non-Acetaminophen Pediatric Acute Liver Failure MNK6106 for Liver Disease (Hepatic Cirrhosis) That in the Past Has Affected the Brain (Hepatic Encephalopathy) A Randomized Comparison of Rifaximin Versus Lactulose in Hospitalized Cirrhotic Patients With Renal Failure A Study of Controlled Lactulose Withdrawal Brain Imaging in Patients With Chronic Liver Disease and Functional Impairment. Investigational Microbiota Restoration Therapeutic for Hepatic Encephalopathy FMT in Cirrhosis and Hepatic Encephalopathy Minimal HePatic Encephalopathy Among CiRrhotics. A Cross SEctional, Clinico-EpidEmiological, Multi-Centre, Study in Patients of PakisTan Cerebral Oxygen, Blood Flow and Ammonia Uptake in Patients With Cirrhosis and an Acute Episode of Hepatic Encephalopathy (HE) Antioxidants and Zinc Improving Minimal Hepatic Encephalopathy In Truck Drivers; a Pilot Study Rifamycin in Minimal Hepatic Encephalopathy iPod Games in Hepatic Encephalopathy MNK-6105 for Patients With Cirrhosis and High Ammonia Levels Affecting Brain Function Efficacy of Albumin Dialysis to Treat Patients With Hepatic Encephalopathy Using The Molecular Adsorbent Recirculating System (MARS) Effect of Rifaximine on Sleep Disorders in Patients Suffering From Hepatic Encephalopathy HEAL STUDY (Hepatic Encephalopathy and Albumin Study) Fecal Transplant in Recurrent Hepatic Encephalopathy Intravenous Branched Chain Amino Acids for Hepatic Encephalopathy in ACLF A Nutritional Approach to Minimal Hepatic Encephalopathy Efficacy of Sildenafil in the Improvement of Cognition and Quality of Life in Patients With Cirrhosis of Liver. A Proof of Concept Study. Oral Acetyl-L-Carnitine Therapy Reduces Fatigue In Hepatic Encephalopathy PEG3350 in ACLF With Hepatic Encephalopathy S. Endotoxin, Inflammatory Mediators and MRS Before and After Treatment in MHE Effect of Music on Attention and Prospective Memory in Hepatic Encephalopathy Albumin Infusion Effects in Mortality in Patients With Cirrhosis and Hepatic Encephalopathy The Safety/Efficacy of Rifaximin With/Without Lactulose in Participants With A History of Recurrent Hepatic Encephalopathy Real World Outcomes Study of Hepatic Encephalopathy Patients’ Experience on Rifaximin (PROSPER) Study of Rifaximin in Minimal Hepatic Encephalopathy PEG (Polyethylene Glycol)Versus Lactulose For Treatment Of Overt Hepatic Encephalopathy A Study of Safety and Efficacy of HPN-100 in Subjects With Cirrhosis and Episodic Hepatic Encephalopathy Safety and Tolerability Study of Rifaximin in Participants With a History of Hepatic Encephalopathy L-ornithine L-aspartate in Overt Hepatic Encephalopathy Efficacy and Safety of Nitazoxanide in Preventing Recurrence of Hepatic Encephalopathy Efficacy Study of Polyethylene Glycol 3350-electrolyte Solution (GoLYTELY®) Versus Lactulose in Patients With Hepatic Encephalopathy. Efficacy of Albumin for Acute Encephalopathy in Patients With Cirrhosis Lactulose for the Prevention of Hepatic Encephalopathy in Cirrhotic Patients With Upper Gastrointestinal Hemorrhage Default Mode Network fMRI Maps as a Predictive Index of Hepatic Encephalopathy Outcome AST-120 Used to Treat Mild Hepatic Encephalopathy The Role of Bacterial Overgrowth and Delayed Intestinal Transit in Hepatic Encephalopathy Rifaximin Plus Lactulose Versus Lactulose Alone for the Treatment of Hepatic Encephalopathy: a Double Blind Randomized Trial Safety and Efficacy of AST-120 Compared to Lactulose in Patients With Hepatic Encephalopathy Late Evening and Early Morning Protein Supplement to Reduce Readmissions for Hepatic Encephalopathy Rifaximin’s Effect on Covert Hepatic Encephalopathy in Cirrhosis Patients With Small Intestinal Bacterial Overgrowth and Gastrointestinal Dysmotility Efficacy of Combined Oral L-Ornithine-L-Aspartate and Lactulose in Patients With Hepatic Encephalopathy Acetyl-L-Carnitine Reduces Depression and Improves Quality of Life in Patients With Minimal Hepatic Encephalopathy Coenzyme Q10 and Meclofenoxate in Hepatic Encephalopathy Effect of Yogurt on Minimal Hepatic Encephalopathy Probiotic Lactobacillus GG (LGG) in Patients With Minimal Hepatic Encephalopathy Efficacy of L-Ornithine L-Aspartate in Acute Hepatic Encephalopathy. Efficacy of L-Ornithine-L-Aspartate in Cirrhotics With Hepatic Encephalopathy Transcranial Doppler Ultrasound and Minimal Hepatic Encephalopathy Brain Muscle Axis During Treatment of Hepatic Encephalopathy With L-ornithine L-aspartate Effect of Lactose in Patients With Chronic Liver Disease and Minimal Hepatic Encephalopathy Fecal Microbiota Transplantation (FMT) in the Management of Hepatic Encephalopathy (HE): a Pilot Study Efficacy and Safety Study of Ammonul® in Patients With Grade 3 or 4 Hepatic Encephalopathy The Effects of Nitazoxanide in Hepatic Encephalopathy Effect of Lactulose on Minimal Hepatic Encephalopathy and Health-Related Quality of Life A 6-month Efficacy, Safety, and Tolerability Study of Rifaximin In Preventing Hepatic Encephalopathy Diagnosis of Covert/Minimal Hepatic Encephalopathy by Means of Continuous Reaction Time Measurement Fecal Transplant for Hepatic Encephalopathy RICE Trial: Rifaximin In Chronic Hepatic Encephalopathy – A Randomized, Controlled Trial Efficacy, Safety, And Pharmacokinetics Of Rifaximin In Subjects With Severe Hepatic Impairment And Hepatic Encephalopathy Phase 2B Efficacy/Safety of Ornithine Phenylacetate in Hospitalized Cirrhotic Patients With Hepatic Encephalopathy (STOP-HE) Rifaximin Soluble Solid Dispersion (SSD) Tablets Plus Lactulose for the Treatment of Overt Hepatic Encephalopathy (OHE) Post Transjugular Intrahepatic Portosystemic Shunt (Tips) Albumine Infusion to Prevent Hepatic Encephalopathy Effects of Proteins in Patients With Cirrhosis and Prior Hepatic Encephalopathy A Retrospective, Open-label, Uncontrolled Cohort Study to Assess the Effectiveness and Safety of Lactulose Retention Enema in the Treatment of Cirrhotic Patients With Grade 3 or 4 (West Haven Criteria) Hepatic Encephalopathy (HE) [The RETRO Study] Fecal Microbiota Transplant as Treatment of Hepatic Encephalopathy Rifaximin in Minimal Hepatic Encephalopathy Role of MRI in Detection of Minimal Hepatic Encephalopathy Cerebrovascular Reactivity in Hepatic Encephalopathy Primary Prophylaxis of Hepatic Encephalopathy in Patients With Cirrhosis Secondary Prophylaxis of Hepatic Encephalopathy in Cirrhosis Secondary Prophylaxis of Hepatic Encephalopathy With a Probiotic Preparation The Role of Bacterial Overgrowth and Delayed Intestinal Transit in Hepatic Encephalopathy. Metformin Experience on Minimal Hepatic Encephalopathy Plasma Free Amino Acids in Patients With Hepatic Encephalopathy Treatment of Hepatic Encephalopathy With Flumazenil and Change in Cortical GABA Levels in MRS Lactulose, L-ornithine L-aspartate, or Rifaximin Versus Placebo for Preventing Hepatic Encephalopathy in Variceal Bleeding Low-dose Rifaximin in the Treatment of Covert Hepatic Encephalopathy Hyperproteic Diet Plus Lactobacillus Reuteri and Nitazoxanide in Minimal Hepatic Encephalopathy Comparison Between Erythromycin and Neomycin Treatment of Hepatic Encephalopathy

Brief Title

GELSECTAN® and Covert Hepatic Encephalopathy

Official Title

Effects of GELSECTAN® Administration on Covert Hepatic Encephalopathy (CHE) in Patients With Cirrhosis.

Brief Summary

      Randomized crossover pilot clinical trial in which 10 cirrhotic patients with covert hepatic
      encephalopathy (CHE) will be assigned to take GELSECTAN® (TID) or placebo for 30 days. After
      a washout period of 15 days, the treatment branches will be interchanged.

      The objective of the trial is to obtain pilot variances to design a phase II trial, in which
      the efficacy of the treatment will be tested. As an exploratory objective, the efficacy of
      the product in the treatment of covert hepatic encephalopathy will be analyzed.

      Main endpoint Improvement in CHE after 30 days of treatment with GELSECTAN®, measured by the
      Psychometric hepatic encephalopathy score (PHES)

Study Type


Primary Outcome

CHE improvement


Covert Hepatic Encephalopathy



Study Arms / Comparison Groups

 Treatment sequence A
Description:  Patients will follow the following treatment sequence:
Treatment with Gelsectan® (30 days)
Washout period (15 days)
Treatment with placebo (30 days)


* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.

Recruitment Information

Recruitment Status

Dietary Supplement

Estimated Enrollment


Start Date

January 30, 2022

Completion Date

July 30, 2022

Primary Completion Date

May 30, 2022

Eligibility Criteria

        Inclusion Criteria:

          1. Age between 18 and 85 years.

          2. Liver cirrhosis defined by a previous liver biopsy or by clinical data.

          3. Presence of minimal hepatic encephalopathy (MHE) defined by two psychometric methods
             (PHES and / or S-ANT and / or Sloop-test).

          4. Adequately informed patients who grant their written consent to participate in the

        Exclusion Criteria:

          1. Alternative neurological diagnosis.

          2. Hepatic encephalopathy stage ≥2 using the adapted West-Haven scale.

          3. Terminal disease. At the discretion of the doctor, where the patient is in an
             irreversible situation, in which hepatic encephalopathy is a final manifestation.

          4. Presence of Acute-on-chronic liver failure defined by the presence of decompensated
             liver cirrhosis with severe organ or multi-organ failure.

          5. MELD score greater than 25 at the time of inclusion.

          6. Hospitalization for any reason.

          7. Neurological or psychiatric comorbidity that makes the evaluation of hepatic
             encephalopathy difficult. This includes patients with mental illnesses (dementia,
             cerebrovascular disease with sequelae, Parkinson's disease, schizophrenia).

          8. Active digestive bleeding. Before inclusion, there must have been a 48-hour period
             without signs of bleeding.

          9. Patients with hypersensitivity or allergy to any of the components of GELSECTAN®
             (grape, pea).

         10. Clinical situations in which the administration of oral feeding is contraindicated.

         11. Active oncological processes, including hepatocarcinoma.

         12. Active infection of any origin.

         13. Acute renal failure (AKI). Defined by the current diagnostic criteria of the KDIGO
             group (Kidney Disease Improving Global Outcomes).

         14. Dehydration Diagnosed by physical examination of the patient.

         15. Severe hyponatremia. Defined by plasma sodium <130 mEq / dl.

         16. Concomitant use of sedative drugs, such as benzodiazepines, morphic or derivatives
             (methadone, tramadol ...)

         17. Active drug and/or alcohol use. In each case of clinical suspicion of drug use, an
             analysis of toxins in urine will be carried out, which includes cocaine, cannabis,
             opiates. All patients with confirmed alcohol consumption greater than 3 UBD in men or
             2 UBD in women will be excluded.

         18. Consumption of drugs currently indicated for the treatment of HE: Lactulose, lactitol
             and antibiotics.

         19. Participation in another clinical trial




18 Years - 85 Years

Accepts Healthy Volunteers



, 938 96 00 25, [email protected]

Location Countries


Location Countries


Administrative Informations



Organization ID


Responsible Party


Study Sponsor

Consorci Sanitari de l'Alt Penedès i Garraf

Study Sponsor

, , 

Verification Date

December 2021